Ferring Looks For Early Microbiome Wins, But Willing To Do Heavy Lifting
Switzerland’s Ferring is diving deep into the microbiome, looking at a range of potential therapy platforms including bacteriophage and probiotics. Its CSO believes a microbiome-based therapeutic approach could benefit dermatological and women’s health conditions, as well as gastro-intestinal disorders.
You may also be interested in...
Ferring announced this morning (Oct. 31) that Michel Pettigrew is retiring as president of the executive board and will be succeeded by CSO Per Falk. The two spoke to Scrip recently and outlined the Swiss-based firm's future strategy.
The Swiss specialty drug company gains a Phase III microbiome product for the prevention of recurrent Clostridium difficile infection and a broader platform for Microbiota Restoration Therapy.
Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.